Hypercoaguable states Flashcards
G to A mutation at base pair 1691 of coagulation factor V which imparts resistance to cleavage by (1)
- activated protein C
refers to factor V Leiden
Heterozygotes have a 5x increased risk of thrombosis and
homozygotes a 50x increased risk
Factor V Leiden
Resistance to cleavage by activated protein C leads to?
increased Factor V and increased thrombin
hypercoagulability which is also called thrombophilia represents a state of increased risk for ?
thrombosis to occur and in particular for venous thrombosis.
3x increased risk of
venous thrombosis
Prothrombin 20210 mutation
single G to A mutation at position 20210
Prothrombin 20210 mutation
elevation of normal (1) levels occurs in Prothrombin 20210 mutation
- prothrombin
Elevated plasma (1) levels from inherited deficiency of cystathione β‐ synthetase imparts an increased risk for (2)
- homocysteine
2. both arterial and venous thrombosis, and atherosclerosis
It is believed that elevated homocysteine levels cause (1) and convert the normal anticoagulant surface of the (2) to a procoagulant state.
- endothelial cell dysfunction
- endothelial cell
refers to cystathione β‐ synthetase deficiency
activated protein C (APC) is a (1) dependent enzyme whose function is to inactivate (2) and stimulate (3)
- vitamin K
- factor Va and factor VIIIa
- fibrinolysis
There are several clinical syndromes associated with protein C deficiency including ?
Heterozygotes: venous thrombosis; Coumadin skin necrosis.
Homozygotes:
neonatal purpura fulminans.
Homozygous deficiency is not compatible with life and heterozygotes are at increased risk for
venous thrombosis and require lifetime anticoagulation therapy
anti-thrombin III deficiency
cofactor for activated protein C (APC)
Protein S
inhibitor of each of the coagulation factor enzyme
systems
antithrombin
The level of protein S is regulated by (1) of the complement system and is reduced in inflammatory
states due to binding to this complement component.
- C4b
Thus when the hereditary deficiency of protein S is combined with these states it poses a very
serious risk for ?
venous thrombosis
What other factors reduce the level of protein S?
inflammation due to C4b complement component
pregnancy
estrogens
What non-inherited diseases also pose increased risk of venous thrombosis?
Obesity, cardiac, neurologic disease; oral contraceptive use; pregnancy; malignancy; surgery; heparin induced thrombocytopenia
Patients with idiopathic DVT or pulmonary embolism have a 3x increased risk of having (1) within 3 years
- an occult malignancy
caused by antibodies against epitopes on proteins which are in some way “unmasked” by phospholipids
Antiphospholipid antibody syndromes
Secondary antiphospholipid antibody syndrome is associated with autoimmune disease most notably?
Lupus Erythematosus.
Manifestations of APS
recurrent arterial and venous thromboemboli; thrombocytopenia; DVT, PE, cerebrovascular events (stroke, TIA), first trimester fetal loss (recurrent); cerebral vein thrombosis, Budd‐Chiari syndrome, digital infarcts and myocardial infarction
Three types of antiphospholipid antibodies are found in APS:
- Anti‐cardiolipin antibodies
- Antibodies to beta‐2 glycoprotein
- “lupus anticoagulant”
The lupus anticoagulant is so named because it produces (1) however note that while this in vitro effect is (1) the in vivo effect is (2)
- prolongation of the PTT assay
2. thrombosis
A test called (1) is prolonged in patients with lupus anticoagulant. The test corrects to normal not with addition of normal plasma (as it would in a factor deficiency) but only with addition of (2)
- Russel Viper venom test
2. excess phospholipid.
White thrombi occurs in (1) system and is composed of (2)
- high flow arterial
2. platelets and WBCs
Red thrombi occurs in (1) system and is composed of (2)
- low flow venous
2. initial platelet plug, RBCs and thrombin
Arterial thrombosis is associated with a number of conditions including?
MI, stroke, PVD, ischemic bowel, vascular disease, DM, hyperlipidemia, hypercholesterolemia, vasculitis, heparin induced thrombocytopenia, TTP, HUS, Purpura fulminas, myeloproliferative neoplasms
homologous with plasminogen, blocks LDL from its clearance receptor
lipoprotein A
inhibits plasminogen activation by preventing it from binding to fibrin and cells
lipoprotein A
increases atherogenesis, decreases fibrinolysis; risk factor for arterial thrombosis
lipoprotein A
Elevated due to enzyme defects and deficiencies of B12, folate, B6
plasma homocysteine
Key risk factors for arterial thrombosis?
lipoprotein A and plasma homocysteine
Treatment of arterial thrombosis caused by elevated levels of homocysteine
folic acid
Treatment of arterial thrombosis
ASA and anti platelet agents
Glycoprotein IIb/IIIa antagonists
Anti fibrin agents –heparin and low MW heparin
Factors which additionally increase risk of thrombosis, particularly venous thrombosis, in patients with inherited thrombotic states?
pregnancy, smoking, immobilization
Dysfibrinogenemia
accelerated clotting
Dysplasminogenemia
reduced plasmin levels